SBFM Sunshine Biopharma Inc.

Nasdaq sunshinebiopharma.com


$ 1.93 $ 0.13 (7.22 %)    

Wednesday, 15-Oct-2025 16:36:37 EDT
QQQ $ 602.61 $ 4.22 (0.71 %)
DIA $ 463.04 $ 0.00 (0 %)
SPY $ 665.11 $ 2.94 (0.44 %)
TLT $ 90.76 $ -0.20 (-0.22 %)
GLD $ 387.41 $ 6.60 (1.73 %)
$ 1.93
$ 1.87
$ 1.80 x 100
$ 1.99 x 150
$ 1.83 - $ 2.10
$ 1.17 - $ 3.90
846,505
na
8.79M
$ -250.02
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-12-2025 06-30-2025 10-Q
2 05-15-2025 03-31-2025 10-Q
3 04-01-2025 12-31-2024 10-K
4 11-05-2024 09-30-2024 10-Q
5 08-16-2024 06-30-2024 10-Q
6 05-20-2024 03-31-2024 10-Q
7 03-28-2024 12-31-2023 10-K
8 11-13-2023 09-30-2023 10-Q
9 08-10-2023 06-30-2023 10-Q
10 05-10-2023 03-31-2023 10-Q
11 04-04-2023 12-31-2022 10-K
12 11-07-2022 09-30-2022 10-Q
13 08-03-2022 06-30-2022 10-Q
14 05-06-2022 03-31-2022 10-Q
15 03-21-2022 12-31-2021 10-K
16 11-09-2021 09-30-2021 10-Q
17 08-09-2021 06-30-2021 10-Q
18 05-11-2021 03-31-2021 10-Q
19 03-30-2021 12-31-2020 10-K
20 11-12-2020 09-30-2020 10-Q
21 08-19-2020 06-30-2020 10-Q
22 05-18-2020 03-31-2020 10-Q
23 05-01-2020 12-31-2019 10-K
24 11-13-2019 09-30-2019 10-Q
25 08-15-2019 06-30-2019 10-Q
26 05-20-2019 03-31-2019 10-Q
27 04-12-2019 12-31-2018 10-K
28 11-16-2018 09-30-2018 10-Q
29 08-17-2018 06-30-2018 10-Q
30 05-22-2018 03-31-2018 10-Q
31 04-02-2018 12-31-2017 10-K
32 11-15-2017 09-30-2017 10-Q
33 08-11-2017 06-30-2017 10-Q
34 05-12-2017 03-31-2017 10-Q
35 04-17-2017 12-31-2016 10-K
36 11-14-2016 09-30-2016 10-Q
37 08-16-2016 06-30-2016 10-Q
38 05-09-2016 03-31-2016 10-Q
39 03-25-2016 12-31-2015 10-K
40 11-04-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 sunshine-biopharma-in-collaboration-with-university-of-arizona-announces-development-of-new-series-of-orally-active-non-covalent-protease-inhibitors-that-show-dose-dependent-antiviral-activity-in-mice-infected-with-sars-cov-2

Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving me...

 aegis-capital-reiterates-buy-on-sunshine-biopharma-maintains-7-price-target

Aegis Capital analyst David Bouchey reiterates Sunshine Biopharma (NASDAQ:SBFM) with a Buy and maintains $7 price target.

 sunshine-biopharma-filed-us-patent-application-20250276036-for-composition-for-the-inhibition-of-nrf2-and-uses-thereof-in-cancer-therapy

https://ppubs.uspto.gov/api/pdf/downloadPdf/20250276036?requestToken=eyJzdWIiOiIyZDUxZWIxMy0xNzcwLTRmZDItYWZhYi1hZDZhM2MxMzVjOT...

 sunshine-biopharma-announces-that-its-wholly-owned-canadian-subsidiary-nora-pharma-has-launched-niopeg-the-companys-first-biosimilar-drug

Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving me...

 sunshine-biopharmas-canadian-subsidiary-nora-pharma-launches-gabapentin-a-new-generic-prescription-drug-in-the-therapeutic-class-of-anticonvulsants

Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving me...

 sunshine-biopharma-launches-oncology-drug-everolimus-in-canada-with-an-estimated-global-market-of-25b

FORT LAUDERDALE, FL / ACCESS Newswire / April 21, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM), a pharmaceutical company offeri...

 sunshine-biopharma-announces-246m-registered-direct-offering-at-207-a-share

FORT LAUDERDALE, FL / ACCESS Newswire / April 2, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharma...

 sunshine-biopharma-stock-shoots-higher-on-encouraging-data-from-mrna-based-liver-cancer-drug

Sunshine Biopharma's K1.1 mRNA-LNP shows promise for HCC treatment in mice, while its 2024 revenue surged 45% to $34.9 mill...

 us-stock-futures-slip-ahead-of-liberation-day-tariffs-announcement-expert-points-to-uncertainty-amid-higher-risk-premia

U.S. stock futures slipped on Wednesday after a mixed session on Tuesday. Futures of major benchmark indices were lower in prem...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION